When security vulnerabilities appear in popular frameworks, they can affect thousands of websites overnight. That’s exactly what’s happening with a newly discovered vulnerability in Next.js – one of ...

One of the key learning outcomes of university education in general, and liberal arts programmes,  in particular, is that ...

Cathie Wood’s ARK Investment Management sharply increased its exposure to AI-driven biotechnology and cryptocurrency during ...

Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

The original version of this story appeared in Quanta Magazine. Among the myriad abilities that humans possess, which ones are uniquely human? Language has been a top candidate at least since ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Recursion Pharmaceuticals, Inc. before investing. In this article, we go over a ...

Sometimes, reading Python code just isn’t enough to see what’s really going on. You can stare at lines for hours and still miss how variables change, or why a bug keeps popping up. That’s where a ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...